How to use donanemab (donanemab-azbt)-Kisunla

Donanemab-azbt (donanemab-azbt)-Kisunla is a disease-modifying therapy indicated for the treatment of Alzheimer's disease (AD). Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stages for whom treatment was initiated in clinical trials. Before starting Kisunlatreatment, the presence of β-amyloid lesions needs to be confirmed.

The recommended dose of Kisunla is 700mg every four weeks for three doses, then 1400mg every four weeks. Kisunla is administered as an intravenous infusion every four weeks for approximately 30 minutes. Kisunla must be diluted before administration. Based on the reduction of amyloid plaques to minimal levels on amyloid PET imaging, consider discontinuing administration of Kisunla. In Study 1, dosing was discontinued based on a decrease in amyloid levels below a predetermined threshold on PET imaging. If an infusion is missed, resume administration as soon as possible at the same dose every 4 weeks.

Kisunlacan cause amyloid-related imaging abnormalities-edema (ARIA-E)and-hemosiderosis (ARIA-H). Before starting treatment with Kisunla, obtain a recent baseline brain magnetic resonance imaging (MRI). Magnetic resonance imaging was performed before the 2nd, 3rd, 4th, and 7th infusions. If a patient develops symptoms suspected of ARIA, a clinical evaluation, including MRI if necessary, should be performed.

For patients who develop intracerebral hemorrhage >1 cm in diameter during treatment with Kisunla, withhold dosing until MRI imaging shows stable imaging and symptoms, if present, resolve. Re-dosing should be guided by clinical judgment. Patients should not take this drug if they have a severe allergic reaction to donanemab-azbt or any ingredient in this infusion.